News

The alliance valued over $750m, and includes a $25m upfront fee, a $10m future equity investment subject to mutual agreement on company valuation, and annual research support for

As part of the Centocor Ortho Biotech collaboration in 2007, a HuCAL antibody became the first from MorphoSys to be developed in two different therapeutic areas – oncology

Under the terms of the agreement, BD is expected to market a number of defined LNA-enhanced products to run on the new BD Max System, BD’s platform for

Ganciclovir for injection is an antiviral drug, which is used for the treatment of Cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS), as

In the trial Caduet (amlodipine besylate/atorvastatin calcium) was associated with a reduced calculated 10-year risk of coronary heart disease (CHD) based on a Framingham risk assessment model. Pfizer

Quotient Bioresearch’s The Old Glassworks is expected to produce radiolabelled compounds for use in both pre-clinical and clinical settings, for its pharmaceutical, biotechnology and agrochemical clients, offering a

IntelGenx said that the two main issues which need to be addressed in order to obtain approval are the qualification of a commercial manufacturing site and the food

Sun Pharma said that, as per the terms of the settlement agreement, it is expected to be able to launch generic versions of 25mg/100mg/200mg and 37.5mg/150mg/200mg strengths of

Novo Nordisk has been in discussion with the FDA regarding further progression of the development programme investigating the potential of Liraglutide within obesity. Based on the feedback from